ID S1034

Defines "anticancer medication" as drugs or biologics used to kill, slow, or prevent growth of cancerous cells, administered orally, intravenously, or by injection.

Prohibits health benefit plans from assigning higher copayments, deductibles, or coinsurance for patient-administered anticancer medications than for injected or intravenously administered anticancer medications when ordered by a licensed oncologist and meeting plan coverage criteria.

Allows health benefit plans to classify anticancer medications as either medical or pharmacy benefits at their discretion.

Prevents plans from circumventing equal cost-sharing requirements by increasing copayments, deductibles, or coinsurance amounts for any anticancer medications or reclassifying benefit categories.

Effective date: January 1, 2020.